GlassScriptPhysician profile
Laura C Farrington
NPI 1073786745
$8,119.61
in general payments reported to CMS, 2019-2025
43 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,816 · 2020: $437 · 2021: $90.08 · 2022: $175 · 2023: $844 · 2024: $3,304 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Consulting Fee: $1,575 · Education: $294 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.48 |
| Consulting Fee | $1,575.00 |
| Education | $293.95 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,817.85 | 2019-2024 | Imfinzi, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $758.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $629.94 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $560.84 | 2021-2025 | Trodelvy |
| Pfizer INC. | $559.42 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $411.20 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $335.53 | 2020-2025 | Enhertu |
| Lilly USA, LLC | $307.55 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $268.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $254.32 | 2019-2020 | |
| Eisai INC. | $188.46 | 2019-2025 | |
| Astellas Pharma US INC | $186.71 | 2019-2024 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $176.42 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.75 | 2019-2024 | Fruzaqla |
| Emd Serono, INC. | $150.00 | 2019-2024 |
Show all 41 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Farrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.